文献速递艾滋病与性传播感染

单剂唑来膦酸可持久抑制HIV初治者抗逆转录病毒治疗所致骨丢失:IIb期试验

Antiretroviral Therapy-Induced Bone Loss Is Durably Suppressed by a Single Dose of Zoledronic Acid in Treatment-Naive Persons with Human Immunodeficiency Virus Infection: A Phase IIB Trial.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该双盲安慰剂对照IIb期试验将63例非骨质疏松、初治成人HIV感染者随机分配至唑来膦酸5mg组或安慰剂组,启动抗逆转录病毒治疗,分析144周长期数据。结果显示,单剂唑来膦酸在48周时使腰椎骨密度较安慰剂高11%,96周和144周仍高9-11%;96周时CTx较安慰剂低62%,但144周时25%差异无统计学意义。结论认为单剂唑来膦酸可在3年内减轻骨吸收和关键骨折部位的骨密度丢失。

要点

  • 单剂唑来膦酸5mg在ART启动时给药,可持久抑制骨吸收并减少骨密度丢失达3年。
  • 96周时CTx较安慰剂低62%,但144周时25%差异无统计学意义。
  • 腰椎BMD在48周高11%,96周和144周仍高9-11%。

核心结论

  • 在初治HIV感染者启动ART时单次给予唑来膦酸5mg,可钝化骨吸收并减少关键骨折部位骨密度丢失达3年。
  • 需多中心随机III期临床试验在更大人群中验证这些结果。

研究设计与样本

  • 双盲、安慰剂对照IIb期试验,随机分配63例非骨质疏松、初治成人HIV感染者至唑来膦酸5mg组或安慰剂组,启动ART。
  • 分析长期结局数据至144周,在0、12、24、48、96和144周定量血浆骨转换标志物和骨密度。
  • 主要结局为骨吸收标志物I型胶原C端肽(CTx)的变化,采用混合线性模型重复测量分析。

主要发现

  • 96周时,唑来膦酸组平均CTx较安慰剂组低62%(n=46;CTx=0.123 vs 0.324 ng/mL;P<.001)。
  • 144周时,两组间25%的差异无统计学意义。
  • 48周时,唑来膦酸组腰椎BMD较安慰剂组高11%(n=60;P<.001),96周(n=46)和144周(n=41)仍高9-11%(P<.001)。
  • 唑来膦酸输注后144周,腰椎BMD无变化(P=.22),但髋部(P=.04)和股骨颈(P=.02)BMD下降。

临床怎么用

  • 对于启动ART的初治HIV感染者,可考虑单剂唑来膦酸5mg以预防ART相关骨丢失,但需权衡获益与风险。
  • 唑来膦酸对腰椎BMD的保护可持续3年,但髋部和股骨颈BMD在144周时出现下降,需监测。

局限性

  • 样本量较小(63例),需更大规模III期试验验证。
  • 144周时CTx差异无统计学意义,长期骨吸收抑制效果可能减弱。
  • 髋部和股骨颈BMD在144周时下降,提示保护作用不完全持久。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Human immunodeficiency virus (HIV) infection and antiretroviral therapy (ART) are associated with bone loss leading to increased fracture rate among persons with HIV (PWH). We previously showed long-acting antiresorptive zoledronic acid (ZOL) prevented ART-induced bone loss through 48 weeks of therapy and here investigate whether protection persisted. METHODS: We randomized 63 nonosteoporotic, treatment-naive adult PWH initiating ART to ZOL (5 mg) versus placebo in a double-blinded, placebo-controlled, phase IIb trial. Here we analyzed the long-term outcome data (144 weeks). Plasma bone turnover markers and bone mineral density (BMD) were quantified at weeks 0, 12, 24, 48, 96, and 144. Primary outcome was change in bone resorption marker C-terminal telopeptide of collagen (CTx). Repeated-measures analyses using mixed linear models were used to estimate and compare study endpoints. RESULTS: At 96 weeks, mean CTx was 62% lower with ZOL relative to placebo (n = 46; CTx = 0.123 vs 0.324 ng/mL; P < .001); at 144 weeks a 25% difference between arms was not statistically significant. At 48 weeks, lumbar spine BMD with ZOL was 11% higher than placebo (n = 60; P < .001) and remained 9-11% higher at 96 (n = 46) and 144 (n = 41; P < .001) weeks. 144 weeks after ZOL infusion, BMD did not change at the lumbar spine (P = .22) but declined at the hip (P = .04) and femoral neck (P = .02). CONCLUSIONS: A single dose of ZOL administered at ART initiation blunts bone resorption and BMD loss at key fracture-prone anatomical sites in treatment-naive PWH for 3 years. A multicenter randomized phase III clinical trial validating these results in a larger population is needed. CLINICAL TRIALS REGISTRATION: NCT01228318.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Ofotokun I, Collins LF, Titanji K, et al. Antiretroviral Therapy-Induced Bone Loss Is Durably Suppressed by a Single Dose of Zoledronic Acid in Treatment-Naive Persons with Human Immunodeficiency Virus Infection: A Phase IIB Trial. Clin Infect Dis. 2020. PMID: 31621838. doi:10.1093/cid/ciz1027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。